Evidence map›Paper›PMID 39587867›Full record

Trial reportClinical pharmacology in drug development2025

Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP-624 in Healthy Adults.

Greg Rigdon, Yuki Prescott, John Hall, Kelly Abernathy, Joel Raskin, William Wargin

Abstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology in drug development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. SIRT3/6/7: promising therapeutic targets for pulmonary fibrosis.Frontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Greg RigdonSirtsei Pharmaceuticals, Inc., a Subsidiary of Arrivo BioVentures, Morrisville, NC, USA.
Yuki PrescottSirtsei Pharmaceuticals, Inc., a Subsidiary of Arrivo BioVentures, Morrisville, NC, USA.
John HallSirtsei Pharmaceuticals, Inc., a Subsidiary of Arrivo BioVentures, Morrisville, NC, USA.
Kelly AbernathySirtsei Pharmaceuticals, Inc., a Subsidiary of Arrivo BioVentures, Morrisville, NC, USA.
Joel RaskinSirtsei Pharmaceuticals, Inc., a Subsidiary of Arrivo BioVentures, Morrisville, NC, USA.
William WarginSirtsei Pharmaceuticals, Inc., a Subsidiary of Arrivo BioVentures, Morrisville, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sirtuin 6 activation is a novel epigenetic mechanism proposed for treatment of depression. Two Phase 1 studies, SP-624-101 and SP-624-102, examined the pharmacokinetics and safety of SP-624, an orally active sirtuin 6 activator, in healthy adults. SP-624-101 was a single-ascending-dose study. In Part A, participants were randomized 6:2 to SP-624 (single oral doses of 3, 10, or 30 mg) or placebo. Part B compared results in 8 participants receiving SP-624 while fasting or after a high-fat, high-calorie breakfast. In SP-624-102, a multiple-ascending-dose study, participants were randomized 6:2 to SP-624 (3 or 10 mg SP-624 daily) or placebo for 5 days and 5:2 to SP-624 20 mg daily or placebo for 10 days. At all doses, maximum concentration (C

Indexed as

BenzofuransFood-Drug InteractionsHealthy VolunteersSirtuinsAdministration, OralAdultArea Under CurveDose-Response Relationship, DrugDouble-Blind MethodFastingFemaleHumansMaleMiddle AgedPlacebosYoung AdultBenzofuransPlacebosSIRT6 protein, humanSirtuinshealthy volunteersPhase 1SIRT6sirtuin 6SP‐624

Identifiers

PMID39587867
PMCPMC11701958

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.